Update: KYV-101 for Treatment of Refractory Lupus Nephritis Appears Safe for First U.S. study participant After 28-Days of Dosing in Phase 1 Study
Currently in the Phase 1 trial for refractory lupus nephritis (LN, lupus-related kidney disease in which people do not respond to first-line immunosuppressive drugs or quickly relapse after remission), Kyverna’s investigational drug, KYV-101, was generally well tolerated by the first U.S. study participant with no signs of concern after 28-days of dosing.
KYV-101 is a CAR-T cell therapy designed to target B cells (immune system cells involved in the production of autoantibodies and lupus disease activity). This therapy targets a protein known as CD19, which is found on the surface of B cells. This particular protein plays a role in several malignancies and autoimmune diseases.
The open-label Phase 1 clinical trial continues to actively recruit study participants, targeting to enroll nine to 12 patients with LN across the US. Additionally, people with lupus are currently under treatment with KYV-101 in Europe for multiple indications.
Continue to follow the Lupus Foundation of America for KYV-101 developments, as well as other lupus drug development news. Learn more about medications used to treat lupus.
Interested in getting research like this straight to your inbox? Subscribe to our bimonthly Inside Lupus Research email for all the latest.